BioSpace News Archive

Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers associated with cognitive impairment, including neuroinflammatory biomarkers; MELAS Phase 2a study underway with top-line data anticipated in mid-2021; Phase 2a study Alzheimer’s disease with vascular pathology expected to initiate in mid-2021;

Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing

We are very impressed by our employees and partners for their resilience and achievements during 2020.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients (“outpatients”) with COVID-19, following recommendations from the Independent Data Monitoring Committee (IDMC).

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST .

Miroculus, Inc., a developer of revolutionary tools for personal lab automation, today announced the completion of a Series B extension, bringing the total capital raised in the series to $45M.

-- Launched EYSUVIS™, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- -- Progressing Pipeline Programs to Address Front and Back of Eye Diseases -- -- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 4Q 2022; EYSUVIS Revenue Expected to Provide Additional Runway --

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter and year end 2020 update and financial results on Thursday, March 4 at 4:30 p.m. ET.

EUSA Pharma (UK) Limited (“EUSA Pharma”), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network® (NCCN®) has updated their Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas to include siltuximab (SYLVANT®)

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual 10 th Annual SVB Leerink Global Healthcare Conference 2021, on Friday, February 26, 2021